메뉴 건너뛰기




Volumn 13, Issue 11, 2011, Pages 1036-1046

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients

Author keywords

Avandamet; Bone mineral density; Drug na ve; FPG; Hb1Ac; Metformin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; TRIACYLGLYCEROL;

EID: 80053403319     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01461.x     Document Type: Article
Times cited : (79)

References (26)
  • 1
    • 0032983666 scopus 로고    scopus 로고
    • Study (UKPDS) Group. UKPDS 49. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies.
    • U.K. Prospective Diabetes
    • U.K. Prospective Diabetes. Study (UKPDS) Group. UKPDS 49. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA 1999; 281: 2005-2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
  • 2
    • 0028817815 scopus 로고
    • UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective
    • U.K. Prospective Diabetes Study Group (UKPDS)
    • U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes 1995; 44: 1249-1258.
    • (1995) Diabetes , vol.44 , pp. 1249-1258
  • 3
    • 0034641568 scopus 로고    scopus 로고
    • UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study.
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 2000; 321: 405-412.
    • (2000) BMJ , vol.321 , pp. 405-412
  • 4
    • 1042280201 scopus 로고    scopus 로고
    • Glycemic control from 1998 to 2000 among U.S. adults diagnosed with type 2 diabetes.
    • Koro CE, Bowlin SJ, Bourgeois B, Fedder DO. Glycemic control from 1998 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 2004; 27: 17-20.
    • (2004) Diabetes Care , vol.27 , pp. 17-20
    • Koro, C.E.1    Bowlin, S.J.2    Bourgeois, B.3    Fedder, D.O.4
  • 5
    • 84878665227 scopus 로고    scopus 로고
    • ACE/AACE Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Available from URL: Accessed September 2009.
    • ACE/AACE Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Available from URL: Accessed September 2009.
  • 6
    • 0347480396 scopus 로고    scopus 로고
    • Clinical use of thiazolidinediones: Recommendations.
    • Abrahamson MJ. Clinical use of thiazolidinediones: Recommendations. Am J Med 2003: 115: 117S-120S.
    • (2003) Am J Med , vol.115
    • Abrahamson, M.J.1
  • 7
    • 33749498694 scopus 로고    scopus 로고
    • Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    • Rosenstock J, Rood J, Cobitz A et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006; 8:650-660.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 650-660
    • Rosenstock, J.1    Rood, J.2    Cobitz, A.3
  • 8
    • 33845405222 scopus 로고    scopus 로고
    • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    • for the ADOPT Study Group
    • Kahn SE, Haffner SM, Heise MA et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
    • (2006) N Engl J Med , vol.355 , pp. 2427-2443
    • Kahn, S.E.1    Haffner, S.M.2    Heise, M.A.3
  • 9
    • 48649095960 scopus 로고    scopus 로고
    • Rosiglitazone-associated fracture in type 2 diabetes.
    • for the ADOPT Study Group
    • Kahn SE, Zinman B, Lachin JM et al. for the ADOPT Study Group. Rosiglitazone-associated fracture in type 2 diabetes. Diabetes Care 2008; 31: 845-851.
    • (2008) Diabetes Care , vol.31 , pp. 845-851
    • Kahn, S.E.1    Zinman, B.2    Lachin, J.M.3
  • 10
    • 67149146438 scopus 로고    scopus 로고
    • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
    • Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
    • (2009) Lancet , vol.373 , pp. 2125-2135
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3
  • 11
    • 0032511583 scopus 로고    scopus 로고
    • UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.
    • U.K. Prospective Diabetes Study Group (UKPDS)
    • U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 12
    • 0032511566 scopus 로고    scopus 로고
    • UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes.
    • U.K. Prospective Diabetes Study Group (UKPDS)
    • U.K. Prospective Diabetes Study Group (UKPDS). UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-865.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 13
    • 0037116638 scopus 로고    scopus 로고
    • Oral antihyperglycemic therapy for type 2 diabetes.
    • Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.
    • (2002) JAMA , vol.287 , pp. 360-372
    • Inzucchi, S.E.1
  • 14
    • 0012893593 scopus 로고    scopus 로고
    • Insulin resistance and B-cell function-a clinical perspective.
    • Matthews D. Insulin resistance and B-cell function-a clinical perspective. Diabetes Obes Metab 2001; 3(Suppl. 1): S28-33.
    • (2001) Diabetes Obes Metab , vol.3 , Issue.SUPPL. 1
    • Matthews, D.1
  • 15
    • 0001285263 scopus 로고    scopus 로고
    • Clinical practice recommendations.
    • ADA
    • ADA, Clinical practice recommendations. Diabetes Care 2010; 33(Suppl. 1): 1s-100s.
    • (2010) Diabetes Care , vol.33 , Issue.SUPPL. 1
  • 16
    • 0038064504 scopus 로고    scopus 로고
    • Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome.
    • Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetes with metabolic syndrome. Endocrine 2003; 20: 215-218.
    • (2003) Endocrine , vol.20 , pp. 215-218
    • Akbar, D.H.1
  • 17
    • 0037031267 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    • Haffner SM, Greenberg AS, Weston WM. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
    • (2002) Circulation , vol.106 , pp. 679-684
    • Haffner, S.M.1    Greenberg, A.S.2    Weston, W.M.3
  • 18
    • 0034999667 scopus 로고    scopus 로고
    • Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.
    • 1930-1935.
    • Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
    • (2001) J Clin Endocrinol Metab , vol.86
    • Weyer, C.1    Funahashi, T.2    Tanaka, S.3
  • 19
    • 0036481709 scopus 로고    scopus 로고
    • Synthetic peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
    • Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferators-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
    • (2002) Diabetes Care , vol.25 , pp. 376-380
    • Yang, W.S.1    Jeng, C.Y.2    Wu, T.J.3
  • 20
    • 14844327755 scopus 로고    scopus 로고
    • Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity?
    • Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? Int J Obes 2005; 29: S17-23.
    • (2005) Int J Obes , vol.29
    • Bouskila, M.1    Pajvani, U.B.2    Scherer, P.E.3
  • 21
    • 61449206180 scopus 로고    scopus 로고
    • Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus.
    • Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 2009; 160: 265-273.
    • (2009) Eur J Endocrinol , vol.160 , pp. 265-273
    • Kanazawa, I.1    Yamaguchi, T.2    Yamamoto, M.3    Yamauchi, M.4    Yano, S.5    Sugimoto, T.6
  • 22
    • 34147154970 scopus 로고    scopus 로고
    • The peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
    • Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 2007; 92: 1305-1310.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 1305-1310
    • Grey, A.1    Bolland, M.2    Gamble, G.3
  • 24
    • 0344061039 scopus 로고    scopus 로고
    • Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    • Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
    • (2003) Diabetes Obes Metab , vol.5 , pp. 163-170
    • Jones, T.A.1    Sautter, M.2    Van Gaal, L.F.3    Jones, N.P.4
  • 25
    • 0042670079 scopus 로고    scopus 로고
    • Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    • Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003; 26: 1685-1689.
    • (2003) Diabetes Care , vol.26 , pp. 1685-1689
    • Fonseca, V.1    Grunberger, G.2    Gupta, S.3    Shen, S.4    Foley, J.E.5
  • 26


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.